Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus subtilis BC01
- Development stage
- Unknown
- Lead developer
- Bionova Lifesciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus subtilis BC01 is a specific strain of the Gram-positive, spore-forming bacterium *Bacillus subtilis* developed by Bionova Lifesciences as a live biotherapeutic product. It is primarily investigated for the treatment of gastrointestinal disorders, specifically diarrhea-predominant irritable bowel syndrome (IBS-D) and functional dyspepsia. The BC01 strain is characterized by its ability to survive gastric transit and colonize the intestinal tract, where it promotes a healthy microbial balance, strengthens the intestinal barrier, and modulates immune activity. In Phase 3 clinical trials, BC01 has been evaluated for its efficacy in reducing abdominal pain and improving stool consistency in patients with IBS-D.
- Other names
- Bacillus subtilis strain BC01
Beyond the preview
Go deeper on bacillus subtilis BC01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus subtilis BC01.